DUBLIN, Aug. 28, 2015 /PRNewswire/ --
Research and Markets
(http://www.researchandmarkets.com/research/zsgg5n/global_and_usa)
has announced the addition of the "Global & USA BioSimilar
Market Analysis to 2021" report to their offering.
The highly awaited US Biosimilar market will be initiated in
September as Sandoz launches its highly awaited filigrastim
biologic, Zarxio. How will the global market react? Will
biosimilars explode into the biologics market? The author reveals
that biosimilars could save the US economy up to $250 billion within the next seven years. A newly
published Global and USA
Biosimilar Market Analysis to 2021 indicates that there is
tremendous interest by big pharma and generics companies in this
industry who are focusing on biosimilar development of Avastin,
Enbrel, Herceptin, Humira and Rituxan.
Global Biosimilar Market
While the U.S. has approved only one biosimilar therapeutic;
Japan, Australia and Europe have approved six, eight and 19
biosimilars respectively. Already, biosimilars have an exemplary
safety track record in the E.U., Japan, and Canada where biosimilars are regularly
competing against biologics for nearly seven years. The E.U. was
the first geographic market to develop the process of authorization
of biosimilars, setting an example for many other developing
markets to follow suit. As of 2015, the E.U. has approved 19
biosimilars, out of 21 submissions, mostly for three reference
biologics such as Somatropin, Epoetin alfa and Filgrastim.
Biosimilars generated revenues of $1.1
million in 2007 and gradually rose to $86.9 million in 2014. During this period, the
market penetration of biosimilars in Europe and emerging markets was only about 8%.
The top five biologics targeted most by biosimilar developers are
Avastin, Enbrel, Herceptin, Humira and Rituxan, which together
generate revenues of about $50
billion annually.
Like most other markets, a competitive biologics market can offer
benefits to consumers by lowering prices and enhancing quality. In
addition, biosimilars have an unblemished safety track record in
the E.U., where biosimilars have been competing against biologics
since 2006. Biosimilars have also proved to have a notable impact
on drug prices. In the E.U., where biosimilars are already
competing with biologics, biosimilars are sold at a 30% discount
compared to branded biologic drugs. In spite of the approval of 21
biosimilars in Europe, only 18% of
the physicians are aware of these similar versions of
biologics.
US Biosimilar Market
With the approval of the first biosimilar in the U.S in early 2015
and the expected patent expiration of 12 biologics by 2020,
biosimilars are expected to competitively penetrate the biologic's
market. Biosimilars have thus become a threat and opportunity for
biotechnology and pharmaceutical sectors. Zarxio (Filgrastim,
Sandoz) will be launched into the U.S. market in September 2015 and will compete with Neupogen
(Amgen) within the US G-CSF market.
Biosimilars will account for 4% to 10% of the biologics market
total by 2020, depending on the number of biosimilars launched in
the U.S. The U.S. is the largest market for biologics and the
biosimilars can achieve 10% of the global sales in 2020, only if
the volume growth for biologics is achieved in the U.S. market. The
main players looking to penetrate the US biosimilar market are
currently Amgen, Mylan, Pfizer, Sandoz and Hospira.
Companies Mentioned - Partial List
- 3SBio
- AET BioTech
- Abzena
- Actavis
- Alvogen
- Amega Biotech
- Amgen
- Anhui Anke Biotechnology (Group) Co., Ltd.
- Apotex
- Avesthagen Ltd.
- Baxter International Inc.
- Beijing Four Rings Biopharmaceutical Co., Ltd.
- Bharat Biotech International Ltd.
- Binovis SA
- BioXpress Therapeutics SA
- Biocon Ltd.
- Biogen Inc.
- Biopartners GmbH
- Biosidus SA
- Biotechnol AS
- Bioton Spolka AKcyjna
- Bioviz Technologies Pvt, Ltd.
- Boehringer Ingelheim GmbH
- Bolder BioTechnology Inc.
- CJSC Biocad
- CT Arzneimittel GmbH
- Cadilla Pharmaceuticals Ltd.
- Celltrion Inc.
- Cerbios-Pharma SA
- Cipla Ltd.
For more information visit
http://www.researchandmarkets.com/research/zsgg5n/global_and_usa
Media Contact: Laura Wood
, +353-1-481-1716, press@researchandmarkets.net